Patents Examined by Michael G. Hartley
  • Patent number: 10098975
    Abstract: The present invention relates to the use of compounds that selectively bind to activated protein kinase G 1 alpha for imaging the anatomic basis for chronic pain. Such imaging may also be used to objectively quantify chronic pain.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 16, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrei O. Koren, Shi-Xian Deng, Donald W. Landry, Chaitanya Divgi
  • Patent number: 10100037
    Abstract: Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: October 16, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Martijn Verdoes
  • Patent number: 10098974
    Abstract: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to arylammonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the ammonium compound is a tetraaryl ammonium salt. Another aspect of the invention relates to arylsulfonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the sulfonium compound is a triaryl sulfonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 16, 2018
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
  • Patent number: 10092521
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: October 9, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Roger A Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Patent number: 10087199
    Abstract: The invention provides compositions that may be used for imaging intracellular structures. The invention further provides methods of imaging intracellular structures. In certain embodiments, the compositions of the invention include trans-cyclooctene-containing ceramide lipids and tetrazine-containing rhodamine-related dyes.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: October 2, 2018
    Assignee: Yale University
    Inventors: Roman Erdmann, Alanna Schepartz Shrader, Derek Toomre
  • Patent number: 10086074
    Abstract: Provided are compositions comprising porphyrin-phospholipid nanovesicles (PoP-NVs) which can be loaded with cargo. Methods for release of cargo from the PoP-NVs triggered by near infrared (NIR) light are also disclosed.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 2, 2018
    Assignees: The Research Foundation for The State University of New York, Health Research, Inc.
    Inventors: Jonathan Lovell, Ravindra Pandey, Kevin Carter, Shuai Shao
  • Patent number: 10086090
    Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 2, 2018
    Assignees: NATIONAL UNIVERSITY CORPORATION MIE UNIVERSITY, NATIONAL UNIVERSITY CORPORATON NAGOYA UNIVERSITY
    Inventors: Katsunori Teranishi, Hitoshi Hirata, Tetsuya Arai
  • Patent number: 10080822
    Abstract: The present application discloses the use of a polyurethane material in the preparation of a latex product, wherein the polyurethane material comprises a waterborne polyurethane and nano-silver. The polyurethane material of the present application is made of a combination of a waterborne polyurethane and nano-silver, which gives rise to the said latex products not only having a broad spectrum of antimicrobial activity including inactivating HIV-1 and HSV, but also having the ability to inactivate the microorganism in a short time.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: September 25, 2018
    Inventors: Rulin Chen, Victor W J Chan
  • Patent number: 10081600
    Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 25, 2018
    Assignee: The McLean Hospital Corporation
    Inventors: John L. Neumeyer, Yu-Gui Si, Anna Waclawa Sromek
  • Patent number: 10076578
    Abstract: Exemplary probes for detecting hypoxic cells and tissue have the structure of
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: September 18, 2018
    Assignee: Vanderbilt University
    Inventors: Ashwath Jayagopal, Kwangho Kim, Gary Sulikowski, Stephanie Evans
  • Patent number: 10076581
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • Patent number: 10076580
    Abstract: The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles having respective peaks of non-linear echographic response differing by at least 2 MHz to each other, and preferably have respective size distributions with different median sizes. In particular, said preparations preferably have size distributions with respective DV50 values differing from each other by at least 0.5 ?m, more preferably at least 1.0 ?m. Alternatively, said composition has a volume size distribution showing a value of Bowley skewness of 0.16 or higher.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 18, 2018
    Assignee: BRACCO SUISSE S.A.
    Inventors: Philippe Bussat, Peter Frinking, Christian Guillot, Michel Schneider
  • Patent number: 10071068
    Abstract: Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: September 11, 2018
    Assignee: XENOPORT, INC.
    Inventors: David E. Edgren, David J. Kidney, Nikhil Pargaonkar, Derrick K. Kim, Gorm Yoder, Sarni Karaborni
  • Patent number: 10071983
    Abstract: Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: September 11, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Doron Shabat, Ronit Satchi-Fainaro
  • Patent number: 10071943
    Abstract: Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 11, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Peter J. H. Scott, Melanie S. Sanford, Naoko Ichiishi, Allen F. Brooks, Melissa Rodnick, Joseph J. Topczewski
  • Patent number: 10064943
    Abstract: The present invention provides compositions and methods of use of nanoparticle-based probes for in vivo imaging and therapy. The probes can be used to track diseased target cells by non-invasive imaging in the near-infrared range. Additionally, the probes can induce cell death of the target cells via photodynamic treatment.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: September 4, 2018
    Assignee: LI-COR, Inc.
    Inventors: David L. Dilley, Joy Kovar
  • Patent number: 10058625
    Abstract: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: August 28, 2018
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
  • Patent number: 10058548
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 28, 2018
    Assignee: GR√úNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomaeus, Heinrich Kugelmann
  • Patent number: 10058713
    Abstract: A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: August 28, 2018
    Assignee: ALPHA TAU MEDICAL LTD.
    Inventors: Itzhak Kelson, Lior Arazi
  • Patent number: 10059704
    Abstract: A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN? groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: August 28, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Sylvain Routier, Franck Suzenet, Frederic Pin, Sylvie Chalon, Johnny Vercouillie, Denis Guilloteau